The FDA has approved Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use, from Merck, as immunotherapy for the...
The Allergenic Products Advisory Committee meeting of the FDA has made a positive recommendation of Ragwitek (Short Ragweed Pollen Allergen Extract)...
ALK Abello announced that the FDA approved Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use for the treatment of short ragweed pollen-induced allergic rhinitis in persons ages five through 65.
ALK announced that Health Canada has approved once-daily Ragwitek (Standardized Allergen Extract, Short Ragweed (Ambrosia artemisiifolia) Sublingual Tablet) for the treatment of moderate to severe ragweed pollen allergies in children age five and older.
Merck announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-8237, Merck’s house dust mite...